44 -1 (39) 2022 — Uroqov Sh.T., Rizaeva M. J. — EFFICIENCY AND SAFETY OF ELECTRIC CARDIOVERSION IN PERSISTENT FORM OF ATRIAL FIBRILLATION

EFFICIENCY AND SAFETY OF ELECTRIC CARDIOVERSION IN PERSISTENT FORM OF ATRIAL FIBRILLATION

Uroqov Sh.T. Bukhara State Medical Institute

Rizaeva M. J. Bukhara State Medical Institute Bukhara Branch of RCEMC. Bukhara, Uzbekistan

Resume

Atrial fibrillation (AF) remains one of the most urgent problems of modern cardiology. This is the most common heart rhythm disorder with a frequency of 1-2% in the general population. The analysis is based on the conclusions about the safety and efficacy of electrical cardioversion against the background of a heart rate control strategy in patients with AF and adequate antithrombotic therapy. The most important threat to AF is thromboembolic complications, for example, the risk of stroke increases by 5 times. Thromboembolic complications associated with AF recur and often result in disability or death. Only adequate antithrombotic therapy can reduce mortality from AF .

Key words: electrical cardioversion, atrial fibrillation, antithrombotic therapy, heart rate.

First page

230

Last page

232

For citation: Uroqov Sh.T., Rizaeva M. J. EFFICIENCY AND SAFETY OF ELECTRIC CARDIOVERSION IN PERSISTENT FORM OF ATRIAL FIBRILLATION //New Day in Medicine 1(39)2022 230-232 https://cutt.ly/xO43fOM

LIST OF REFERENCES:

1. RSC, RSSA, RACVS guidelines for the electrophysiological studies, catheter ablation and implantable use of antiarrhythmic devices. Available at: http://www.vnoa.ru/literature/Recomend2013.pdf. Accessed by 1 5/08/2014. Russian (Clinical recommendations of the RKO, VNOA and ASSH on electrophysiological studies, catheter ablation and the use of implantable antiarrhythmic devices. Available at: http://www.vnoa.ru/literature/Recomend2013.pdf. Retrieved 1 5.08.201 4).
2. Hylek E.M., Go A.S., Chang Y. et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1 019-26.
3. Thrall G., Lane D., Carroll D., Lip G.Y. Quality of life in patients with atrial fibrillation: a systematic review. //Am J Med 2006; 1 19: 448 e1-e19.
4. Roy D., Talajic M., Nattel S. et al. Rhythm control versus rate control for atrial fibrillation and heart failure // N. Engl. J. Med.- 2008. – Vol. 358. – P. 2667-2677.
5. Hsu L.F., Jais P., Sanders P. et al. Catheter ablation for atrial fibrillation in congestive heart failure // N. Engl. J. Med. – 2004. – Vol. 351. – P. 2373-2383.
6. Khan M.N., Jais P., Cummings J. et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure // N. Engl. J. Med. – 2008. – Vol. 359. – P. 1778-1785.
7. Kirchhof P., Auricchio A., Bax J., et al. Outcome parameters for trials in atrial fibrillation: executive summary. Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eur Heart J 2007; 28: 2803-17.
8. Ezekowitz M.D., Cappato R. Klein A.L., Camm A.J. et al. Rationale and design of the eXplore the efficacy and safety of once-daily oral rivaroxaban for the prevention of cardiovascular events in patients with nonvalvular atrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion // Am. Heart J. – 2014. – Vol. 167(5). – P. 646-652.
9. Rizayeva Malika Jamolovna. “Improvement of methods of treatment of persistent atrial fibrillation in patients with ischemic heart disease”, //IEJRD Journal, vol. 5, no. SPECIAL ISSUE, p. 7, Dec. 2020.
10. Pulatova Sh.Kh. Method of improving vasopressor therapy for acute myocardic infarction complied with cardiogenic shock 911. //American Journal of Medicine and Medicine Sciences 2020. Vol.10. ISSN: 2165-901X http://journal.sapub.org/ajmms